Delafloxacin

Baxdela

300 MG / VIAL Powder For SolutionCanadaMarketedAuthorised 2 Feb 2026

In other countries

The same active substances on other registers, the same brand first.

BaxdelaSaudi Arabia · Patheon Italia S.P.A.Same brand
BaxdelaSaudi Arabia · AustarPharma LLCSame brand
BaxdelaUnited States · 300MG BASE/VIAL · powder · MelintaSame brand
BaxdelaUnited States · 450MG BASE · tablet · MelintaSame brand
DelabaxiBrazil · Eurofarma Laboratorios S.A.Same substance
delafloxacino megluminaBrazil · Eurofarma Laboratorios S.A.Same substance
QUOFENIX 300 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONSpain · 310 mg · polvo para concentrado para solución para perfusión · A. Menarini Industrie Farmaceutiche Riunite S.R.L.Same substance

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Delafloxacin

Baxdela

300 MG / VIAL Powder For SolutionCanadaMarketedAuthorised 2 Feb 2026

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

QUOFENIX 450 mg COMPRIMIDOSSpain · 649,35 mg · comprimido · A. Menarini Industrie Farmaceutiche Riunite S.R.L.

QuofenixEuropean Union · A. Menarini Industrie Farmaceutiche Riunite s.r.l.

QuofenixCroatia

QuofenixItaly · Compressa · A. Menarini Industrie Farmaceutiche Riunite S.R.L.

Quofenix 300 mg, poeder voor concentraat voor oplossing voor infusieNetherlands · Poeder voor concentraat voor oplossing voor infusie · A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Quofenix 450 mg, tablettenNetherlands · Tablet · A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Documents

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Delafloxacin
Strength: 300 MG / VIAL
Dosage form: Powder For Solution
Route: Intravenous
Register: Canada (Health Canada)
Status: Marketed
Authorised: 2 Feb 2026
Registration: DIN 02554437
Marketing authorisation holder: Xediton Pharmaceuticals INC
ATC code: J01MA23
Group: Anti-infectives for systemic use
Supply: PRESCRIPTION